Archive · 24 Sep 2025
Bombay HC Slams Drug Regulators for Illegal Pharma Orders
The Bombay High Court ruled that drug regulators acted unlawfully by ordering two pharmaceutical companies to stop making certain medicines.
The court found the regulators did not follow the correct legal process, including giving the companies a chance to respond before stopping production.
The orders were in response to concerns about misuse of the medicines in West Africa.
The court stated that even when public health is at risk, authorities must follow the law.
The ruling allows the companies to resume manufacturing other medicines.
Bombay High Court quashed stop-production orders against two pharma companies.
The orders were issued by Maharashtra FDA and CDSCO.
Court found regulators violated legal procedures.
Orders halted manufacturing of medicines with Tapentadol and Carisoprodol.
Ruling allows companies to resume production of other medicines.
- Who
- Bombay High Court, Maharashtra FDA, CDSCO, and two pharma companies.
- What
- Court quashed stop-production orders against pharma firms.
- When
- Orders were issued in February and July 2025; ruling on September 24, 2025.
- Where
- Bombay, India
- Why
- Regulators violated legal procedures by halting production without proper hearings.
- Court
- Bombay High Court
- Regulators Involved
- Maharashtra FDA and CDSCO
- Companies Affected
- National Pharmaceuticals and Aveo Pharmaceuticals
- Orders Quashed
- February 2025 and July 2025 stop-production orders
- Drugs Involved
- Medicines with Tapentadol and Carisoprodol